
Opinion|Videos|May 29, 2024
Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting
Ke Ning, MD, describes similarities and differences when implementing bispecific antibodies and CAR T-cell therapy for patients with relapsed or remitting multiple myeloma in the community oncology setting.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants National Priority Vouchers to Enlicitide Decanoate, Sacituzumab Tirumotecan
2
Beyond Injections: Orforglipron and the Future of Oral GLP-1 Receptor Agonist Therapy
3
Surveys Find Significant Gaps in Public’s Understanding of Shared Decision-Making on Vaccinations
4
Megestrol Acetate’s Role in Early-Stage ER-Positive Breast Cancer
5















































































































































































































